Kyverna Therapeutics Inc Dossier - Source-backed chat

Kyverna Therapeutics Inc

KYTXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.66

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $6.52Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $403.2M

Enterprise Value $396.3M

Shares Outstanding 61.7M diluted

Next Earnings Date11 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Kyverna Therapeutics is a late-stage clinical biopharmaceutical company leading the translation of CAR T-cell therapies from oncology into autoimmune diseases. Its lead candidate, mivocabtagene autoleucel (miv-cel, KYV-101), has demonstrated unprecedented clinical efficacy and a favorable safety profile in neurological autoimmune indications. With a rolling BLA submission initiated for Stiff-Person Syndrome (SPS) and an ongoing Phase 3 trial in generalized myasthenia gravis (gMG), Kyverna is positioned to potentially launch the first FDA-approved autoimmune CAR-T therapy. Backed by a robust cash runway extending into 2028, the company is well-insulated from near-term dilution, presenting an asymmetric risk-reward profile for long-term biotech investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$25.00

Mean target$30.40

High · most bullish analyst$33.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The FDA requests additional clinical data or raises manufacturing CMC concerns during the BLA review for miv-cel in SPS, delaying approval timelines. Competitors with larger capital reserves (e.g., Bristol Myers Squibb) accelerate their clinical timelines, eroding Kyverna's first-mover advantage. High cash burn rates pressure the balance sheet, forcing dilutive financing before commercial self-sustainability is reached.

Base CaseCentral scenario

Kyverna successfully completes its rolling BLA submission for miv-cel in SPS by late 2026, leading to FDA approval and commercial launch in 2027. The Phase 3 gMG trial continues to show robust, durable responses, establishing a multi-indication neuroimmunology franchise. The stock re-rates toward consensus analyst targets as commercial readiness is established.

Bull CaseUpside scenario

Kyverna is positioned to pioneer the autoimmune CAR T space, leveraging miv-cel as a potential first-in-class therapy for severe B-cell-driven autoimmune diseases. Recent regulatory alignment enables a rolling BLA submission for SPS, with pivotal single-arm Phase 2 data showing strong efficacy and safety, targeting FDA approval by late 2026. KYTX maintains a cash runway through 2028, supported by $236M in cash and a $150M credit facility, enabling completion of key trials and commercial launch preparation. The investment thesis hinges on miv-cel's platform potential beyond SPS, notably in gMG and other large autoimmune indications, creating asymmetric upside if regulatory and commercial milestones are met.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-mover advantage with the initiation of a rolling BLA submission for miv-cel in Stiff-Person Syndrome (SPS).
Strong clinical data showing 100% of SPS patients in the KYSA-8 trial were able to discontinue chronic immunotherapies.
Robust balance sheet with $236.4 million in cash and marketable securities, providing a runway into 2028.
Experienced leadership team with deep expertise in cell therapy commercialization from Kite Pharma (Gilead).

Key Investment Risks

Regulatory risks associated with the FDA's review of a single-arm Phase 2 trial (KYSA-8) for BLA approval.
Intense competition from well-capitalized pharmaceutical giants and specialized biotech peers in the autoimmune CAR-T space.
Execution and operational risks in scaling autologous cell therapy manufacturing and commercial distribution.

Thesis Invalidation Triggers

FDA refusal to file or issuance of a Complete Response Letter (CRL) for the miv-cel SPS BLA.
Safety signals such as high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) in ongoing trials.
Severe delays in Phase 3 gMG trial enrollment or failure to meet primary endpoints.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.